Expertise in
8
conditions

Dr. Parvin F. Peddi

Oncology
2121 Santa Monica Boulevard, Garden Level, 
Santa Monica, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
8
conditions
2121 Santa Monica Boulevard, Garden Level, 
Santa Monica, CA 

Overview

Parvin Peddi is an Oncologist practicing medicine in Santa Monica, California.

Dr. Peddi is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

She is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 7 clinical trials. Dr. Peddi is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center
Saint John's Health Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

2121 Santa Monica Boulevard, Garden Level, Santa Monica, CA 90404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Biological
Study Drug: Sacituzumab Govitecan
Study Phase: Phase 2
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drug: Afuresertib
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer
A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: April 08, 2022
Intervention Type: Drug
Study Drugs: LY3023414, Midazolam, Fulvestrant, Pemetrexed, Cisplatin, Abemaciclib, Letrozole
Study Phase: Phase 1
Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.
Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.
Enrollment Status: Completed
Publish Date: September 21, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
View 5 Less Clinical Trials

20 Total Publications

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 22, 2023
Similar Doctors
Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

UCLA Health Bowyer Oncology Center

200 UCLA Medical Plz Ste 120, 
Los Angeles, CA 
 (3.5 miles away)
310-206-6745
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gary Schiller is an Oncologist practicing medicine in Los Angeles, California. Dr. Schiller is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Premiere Oncology A Medical Corporation

2020 Santa Monica Blvd Ste 600, 
Santa Monica, CA 
 (0.4 miles away)
310-829-5471
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Garon is an Oncologist practicing medicine in Santa Monica, California. Dr. Garon is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Premiere Oncology A Medical Corporation

2020 Santa Monica Blvd Ste 600, 
Santa Monica, CA 
 (0.4 miles away)
310-829-5471
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Zev Wainberg is an Oncologist practicing medicine in Santa Monica, California. Dr. Wainberg is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Junction Cancer, Pancreatic Cancer, Stomach Cancer, Pancreaticoduodenectomy, and Tissue Biopsy.

Frequently Asked Questions about Dr. Parvin F. Peddi

How do I make an appointment with Dr. Parvin F. Peddi?

You can book an appointment with Dr. Parvin F. Peddi by calling their office at 310-582-7100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Parvin F. Peddi a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Parvin F. Peddi is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Parvin F. Peddi specialize in?

While Dr. Parvin F. Peddi is a Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Parvin F. Peddi participate in research or clinical trials?

Yes. Dr. Parvin F. Peddi has published 20 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Parvin F. Peddi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Parvin F. Peddi accept my insurance?

Dr. Parvin F. Peddi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-582-7100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Peddi's expertise for a condition
ConditionClose
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile